A phase I-II study of COX-2 inhibitor, Celebrex (Celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

被引：2
|
作者：
Gaffney, DK
Winter, K
Dicker, A
Miller, B
Jhingran, A
Ryu, J
Avizonis, V
Fromm, M
Greven, K
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] RTOG, Philadelphia, PA USA
[3] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[4] Wake Forest Univ, Winston Salem, NC 27109 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Calif Davis, Sacramento, CA 95817 USA
[7] LDS Hosp, Salt Lake City, UT USA
[8] Akron Gen Med Ctr, Akron, OH USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页码：S93 / S94
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant radiochemotherapy for locally advanced gastric cancer:: a phase I-II study
    Roth, AD
    Allal, AS
    Bründler, MA
    de Peyer, R
    Mermillod, B
    Morel, P
    Huber, O
    ANNALS OF ONCOLOGY, 2003, 14 (01) : 110 - 115
  • [22] Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients with locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 0213
    Gore, Elizabeth M.
    Bae, Kyounghwa
    Langer, Corey
    Extermann, Martine
    Movsas, Benjamin
    Okunieff, Paul
    Videtic, Gregory
    Choy, Hak
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S853 - S854
  • [23] A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma
    Zarbá, JJ
    Jaremtchuk, AV
    Jazey, PG
    Keropian, M
    Castagnino, R
    Mina, C
    Arroyo, G
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1285 - 1290
  • [24] A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer: Presentation of safety data
    Duska, L. R.
    Scalici, J. M.
    Petroni, G. R.
    Showalter, T. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 10 - 10
  • [25] A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
    M McCormack
    L Kadalayil
    A Hackshaw
    M A Hall-Craggs
    R P Symonds
    V Warwick
    H Simonds
    I Fernando
    M Hammond
    L James
    A Feeney
    J A Ledermann
    British Journal of Cancer, 2013, 108 : 2464 - 2469
  • [26] A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
    McCormack, M.
    Ledermann, J. A.
    Hall-Craggs, M. A.
    Symonds, R. P.
    Warwick, V.
    Simonds, H.
    Fernando, I.
    Hackshaw, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
    McCormack, M.
    Kadalayil, L.
    Hackshaw, A.
    Hall-Craggs, M. A.
    Symonds, R. P.
    Warwick, V.
    Simonds, H.
    Fernando, I.
    Hammond, M.
    James, L.
    Feeney, A.
    Ledermann, J. A.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2464 - 2469
  • [28] A phase II study of gemcitabine and oxaliplatin in combination with celecoxib in patients with advanced pancreatic tumors overexpressing cyclooxygenase-2 (COX-2)
    Berardi, R.
    Scartozzi, M.
    Silva, R.
    Mari, D.
    Massacesi, C.
    Verdecchia, L.
    Carbonari, G.
    Cascinu, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 225 - 225
  • [29] A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer
    Hussain, SA
    Moffitt, DD
    Glaholm, JG
    Peake, D
    Wallace, DMA
    James, ND
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 929 - 935
  • [30] A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer
    S. J. Dawson
    M. Michael
    J. Biagi
    K. F. Foo
    M. Jefford
    S. Y. Ngan
    T. Leong
    A. Hui
    A. D. Milner
    R. J. S. Thomas
    J. R. Zalcberg
    Investigational New Drugs, 2007, 25 : 123 - 129
12345